Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Oncología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.
INTERVENTIONAL
Inicio: 1 de jul de 2003
ID: NCT00065468
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination With Venetoclax With and Without Obinutuzumab Compared to Investigator's Choice of Chemoimmunotherapy in Subjects With Previously Untreated Chronic Lymphocytic Leukemia Without Del(17p) or TP53 Mutation (AMPLIFY)
INTERVENTIONAL
Inicio: 25 de feb de 2019
ID: NCT03836261
Reclutando
Fase 1
ClinicalTrials.gov
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects With Advanced Solid Tumors
INTERVENTIONAL
Inicio: 2 de jul de 2024
ID: NCT06431594
Completado
Fase 3
ClinicalTrials.gov
A Randomized Phase III Study Comparing Upfront Debulking Surgery Versus Neo-Adjuvant Chemotherapy in Patients With Stage IIIC or IV Epithelial Ovarian Carcinoma
INTERVENTIONAL
Inicio: 1 de sept de 1998
ID: NCT00003636
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 2/3, Adaptive, Randomized, Open-label, Clinical Study to Evaluate Neoadjuvant and Adjuvant Intismeran Autogene (mRNA-4157) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care, and Pembrolizumab Monotherapy in Participants With Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (INTerpath-007)
INTERVENTIONAL
Inicio: 18 de abr de 2024
ID: NCT06295809
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
INTERVENTIONAL
Inicio: 23 de sept de 2020
ID: NCT04497844
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
INTERVENTIONAL
Inicio: 7 de jul de 2017
ID: NCT03138512
Desconocido
ClinicalTrials.gov
Multicentre, Open Label, Extension Study of Treatment With Gefitinib(IRESSA™) for Patients Completing Other Gefitinib Clinical Studies Who May Benefit From Gefitinib Treatment
EXPANDED_ACCESS
ID: NCT00683306
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
INTERVENTIONAL
Inicio: 22 de feb de 2021
ID: NCT04697628
Completado
Fase 3
ClinicalTrials.gov
A Randomized Three-Arm, Multicenter Comparison of 1 Year and 2 Years of Herceptin Versus No Herceptin in Women With HER2-Positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy
INTERVENTIONAL
Inicio: 1 de nov de 2001
ID: NCT00045032
Desconocido
ClinicalTrials.gov
Real World Evidence of First Line Treatment With Intensive Chemotherapy in Adult Patients With Acute Myeloid Leukemia From 18 to 70 Years Old
OBSERVATIONAL
Inicio: 1 de mar de 2021
ID: NCT05127798
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy
INTERVENTIONAL
Inicio: 3 de abr de 2013
ID: NCT01772472
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined With Intravesical BCG in Participants With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
INTERVENTIONAL
Inicio: 2 de ago de 2018
ID: NCT03519256
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
INTERVENTIONAL
Inicio: 12 de dic de 2018
ID: NCT03742895
Completado
ClinicalTrials.gov
An Observational Study of the Safety and Effectiveness of Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Treated in Argentina
OBSERVATIONAL
Inicio: 31 de ago de 2017
ID: NCT03059251
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer
INTERVENTIONAL
Inicio: 1 de mar de 2003
ID: NCT00056407
Completado
Fase 3
ClinicalTrials.gov
A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
INTERVENTIONAL
Inicio: 1 de nov de 2007
ID: NCT00554229
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
INTERVENTIONAL
Inicio: 12 de oct de 2022
ID: NCT05502237
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)
INTERVENTIONAL
Inicio: 19 de jul de 2023
ID: NCT05933577
Completado
Fase 2
ClinicalTrials.gov
Open-label, Multicenter, Phase II Immunotherapy Study With Racotumomab in Patients With High-risk Neuroblastoma
INTERVENTIONAL
Inicio: 1 de nov de 2016
ID: NCT02998983
Anterior
1
...
61
62
63
...
434
Siguiente
Filtros